Clinical trial
Prevention Of Nephrotoxicity Following Bone Marrow Transplantation Using…
NCT00390624 · Rocky Mountain Cancer Centers, Other · Completed
Key facts
| NCT number | NCT00390624 |
|---|---|
| Title | Prevention Of Nephrotoxicity Following Bone Marrow Transplantation Using Urodilatin and Mannitol |
| Official title | Prevention Of Nephrotoxicity Following Allogeneic Bone Marrow Transplantation Using Urodilatin (Ularitide,Atrial Natriuretic Peptide) and Mannitol. |
| Lead sponsor | Rocky Mountain Cancer Centers, Other |
| Collaborators | University of Colorado, Denver |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Renal Dysfunction, Acute Renal Failure, Mortality |
| Intervention type | Drug |
| Interventions | URODILATIN (ULARITIDE, ATRIAL NATRIURETIC PEPTIDE), MANNITOL |
| Enrollment | 20 |
| Start date | Jul 1, 2003 |
| Primary completion | Dec 1, 2006 |
| Completion | Dec 1, 2006 |
| First posted | Oct 20, 2006 |
| Last update posted | Jun 3, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: